Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2021 07:00 ET | Source: Annexon Biosciences

Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business Highlights

SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Today Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies...
March 01, 2021 07:00 ET | Source: Annexon Biosciences

Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy

SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients...
February 08, 2021 07:00 ET | Source: Annexon Biosciences

Annexon Welcomes William H. Carson, M.D. to the Board of Directors

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for...
January 12, 2021 07:00 ET | Source: Annexon Biosciences

Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement Therapeutics

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for...
January 05, 2021 07:00 ET | Source: Annexon Biosciences

Annexon to Present at the J.P. Morgan 39th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for...
December 21, 2020 07:00 ET | Source: Annexon Biosciences

Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients...
November 16, 2020 16:01 ET | Source: Annexon Biosciences

Annexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights

– Cash balance of $370.7 million as of September 30, 2020 bolstered by July IPO –– Recently expanded ANX005 clinical program into neurodegeneration, with initiation of Phase 2 in Huntington’s Disease...
November 12, 2020 16:05 ET | Source: Annexon Biosciences

Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease Clinical Program

– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb – SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage...
September 08, 2020 16:01 ET | Source: Annexon Biosciences

Annexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

– Completed $263M IPO in July, and private financing in late June – – Company plans to initiate four new clinical trials by year-end, including in three expanded indications for ANX005 and...
July 30, 2020 08:00 ET | Source: Annexon Biosciences

Annexon Biosciences Expands Leadership Team with the Appointment of Michael Overdorf as Chief Business Officer

SOUTH SAN FRANCISCO, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with...